Clinical trials: psoriasis
Plaque Psoriasis
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
- Trial name
- ESTEEM 2 (NCT01232283)
- Testing
- Apremilast, Topical or Phototherapy Therapy
- Where
- 46 sites in United States, Austria and 7 more
- Volunteers
- 413 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis
Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy
Study Status: Duke University Health System Institutional Review Board has received notification of study termination; final IRB closure date is 12/12/2008. Study enrollment is now closed.
- Trial name
- NCT00953329
- Testing
- alefacept
- Volunteers
- 1 people
- Sponsor
- John Murray
Psoriatic Arthritis
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
- Trial name
- NCT00267956
- Testing
- CNTO 1275 63 mg
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Centocor, Inc.
Psoriasis
Photocil (Topical) for the Treatment of Psoriasis Vulgaris
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight.
- Trial name
- NCT01916629
- Testing
- Photocil for Psoriasis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Applied Biology, Inc.
Psoriatic Arthritis
Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying…
- Trial name
- NCT00534313
- Testing
- Abatacept
- Where
- 44 sites in United States, Argentina and 10 more
- Volunteers
- 191 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00691002
- Testing
- Calcipotriol plus hydrocortisone (LEO 80190), LEO 80190 Vehicle, Hydrocortisone
- Where
- 11 sites in Croatia, Germany and 2 more
- Volunteers
- 1,245 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 2 (NCT05364554)
- Testing
- JNJ-77242113
- Where
- 60 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Psoriatic Oligoarthritis Intervention With Symptomatic thErapy
POISE is a two arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests less aggressive early therapy in patients newly diagnosed with low impact oligoarticular PsA.
- Trial name
- POISE (NCT03797872)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- University of Oxford
Psoriasis
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness…
- Trial name
- CARIMA (NCT02559622)
- Testing
- Secukinumab
- Where
- 23 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis
Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis
- Trial name
- NCT02462122
- Testing
- IDP-118 Lotion, IDP-118 Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 215 people
- Sponsor
- Bausch Health Americas, Inc.
Ankylosing Spondylitis, Arthritis, Psoriatic
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly.
- Conditions
- Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Spondylitis, Ankylosing
- Trial name
- NCT00273858
- Testing
- There is no Intervention. The study is observational.
- Where
- 9 sites in Greece
- Volunteers
- 880 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.
- Trial name
- NCT01245140
- Testing
- alitretinoin
- Where
- 8 sites in France, Germany and 2 more
- Volunteers
- 33 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis, Skin or Nails
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
Psoriasis is a common skin disease that can affect 1-3% of the population. For more severe psoriasis, oral medication such as acitretin is sometimes given.
- Trial name
- NCT02181790
- Testing
- Excimer laser, Acitretin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Nail Psoriasis
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
- Trial name
- NCT04227288
- Testing
- Enstilar Foam
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Arthritis, Psoriatic
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis…
- Trial name
- NCT01087788
- Testing
- CZP 200 mg Q2W, CZP 400 mg Q4W
- Where
- 92 sites in United States, Argentina and 13 more
- Volunteers
- 409 people
- Sponsor
- UCB BIOSCIENCES GmbH
Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- Opportuniti (NCT04785326)
- Testing
- DMB-3115, Stelara
- Where
- 2 sites in United States
- Volunteers
- 598 people
- Sponsor
- Dong-A ST Co., Ltd.
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and…
- Trial name
- NCT01007591
- Testing
- LEO 80190, Hydrocortisone
- Where
- France
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Psoriatic Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).
- Trial name
- NCT05153148
- Testing
- NDI-034858
- Where
- 56 sites in United States, Czechia and 2 more
- Volunteers
- 305 people
- Sponsor
- Takeda
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC